U.S. markets close in 2 hours 46 minutes
  • S&P 500

    3,890.32
    +79.17 (+2.08%)
     
  • Dow 30

    31,484.24
    +551.87 (+1.78%)
     
  • Nasdaq

    13,497.99
    +305.64 (+2.32%)
     
  • Russell 2000

    2,266.25
    +65.20 (+2.96%)
     
  • Crude Oil

    60.52
    -0.98 (-1.59%)
     
  • Gold

    1,724.00
    -4.80 (-0.28%)
     
  • Silver

    26.67
    +0.23 (+0.85%)
     
  • EUR/USD

    1.2038
    -0.0049 (-0.41%)
     
  • 10-Yr Bond

    1.4480
    -0.0120 (-0.82%)
     
  • GBP/USD

    1.3908
    -0.0015 (-0.10%)
     
  • USD/JPY

    106.8610
    +0.3590 (+0.34%)
     
  • BTC-USD

    48,735.68
    +5,198.91 (+11.94%)
     
  • CMC Crypto 200

    974.50
    +46.27 (+4.98%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Abiomed's (ABMD) ECMO Technology Completes Successful Treatment

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Abiomed, Inc. ABMD recently announced that it has been successful in treating the first two patients in the world with help of its Breethe OXY-1 System, which is a compact cardiopulmonary bypass system. Notably, the Breethe system expedited early mobilization and physical rehabilitation, which is of extreme importance in patient recovery.

Its worthy of mentioning that the Breethe system received FDA 510(k) clearance in October and is being rolled out via a controlled introduction at select hospitals in the United States. Full U.S. commercial availability is anticipated in 2021.

This announcement is likely to provide a boost to Abiomed’s highly exclusive and robust Impella product line.

More on the News

The advanced ECMO technology pumps in the Breethe system can pump, oxygenate and remove carbon dioxide from blood for those patients whose lungs cannot offer required end organ oxygenation. Patients suffering from cardiogenic shock or respiratory failure from acute respiratory distress syndrome (ARDS) H1N1 (influenza strain), severe acute respiratory distress syndrome (SARS) or COVID-19 can get oxygenation through this system.




Notably, this system is a crucial new option for COVID-19 infected patients needing ECMO therapy.

The combination of the Breethe system and Impella heart pump can help in unloading the heart and oxygenating the body. Notably, this therapy is know as ECpella.

This system is an important addition to Abiomed’s solid and innovative portfolio that is focused on native heart and lung recovery.

Market Prospects

Per a report by Grand View Research, the global cardiovascular devices market is anticipated to witness a CAGR of 6.6% over the forecast period (2016-2024). The rising prevalence of chronic heart diseases and sedentary lifestyles are key factors driving this market. Hence, this announcement is a well-timed one for Abiomed.

Recent Developments

In November, Abiomed announced that 1,000 patients have been successfully treated with the Impella 5.5 with SmartAssist heart pump in the first year post FDA approval. The FDA granted Impella 5.5 with SmartAssist its highest level of approval for safety and success.

In October, the company announced that first two patients have been treated with the Impella ECP expandable percutaneous heart pump — the smallest heart pump in the world.

Price Performance

Over the past year, shares of this Zacks Rank #3 (Hold) company have soared 77.5% compared with the industry’s growth of 16.4%.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Merit Medical Systems, Inc. MMSI, Patterson Companies, Inc. PDCO and McKesson Corporation MCK, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Merit Medical has a projected long-term earnings growth rate of 12.6%.

Patterson Companies has an estimated long-term earnings growth rate of 9.6%.

McKesson has a projected long-term earnings growth rate of 6.6%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
McKesson Corporation (MCK) : Free Stock Analysis Report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
 
Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research